Recurrent Uterine Sarcoma: Clinical Trials

9 trials for Recurrent Uterine Sarcoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 terminated. 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Terminated 1

Follow Recurrent Uterine Sarcoma: new trials by email Literature Review of Recurrent Uterine Sarcoma trials Research Report on Recurrent Uterine Sarcoma

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus
temsirolimus - Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Phase 2TerminatedNational Cancer Institute (NCI)82010-01-012016-11-09
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
therapeutic angiotensin-(1-7), laboratory biomarker analysis - Bone Cancer, Chondrosarcoma
Phase 2CompletedWake Forest University Health Sciences202009-10-012018-07-05
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
stereotactic radiosurgery, quality-of-life assessment - Fallopian Tube Cancer, Ovarian Sarcoma
Phase 2CompletedCase Comprehensive Cancer Center502009-05-012013-11-28
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
saracatinib - Adult Fibrosarcoma, Adult Leiomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)172008-02-012018-06-29
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
sunitinib malate - Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma
Phase 2CompletedNational Cancer Institute (NCI)442006-10-012019-07-23
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer
Phase 2CompletedNational Cancer Institute (NCI)632006-09-012015-12-07
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
sorafenib tosylate - Adult Angiosarcoma, Adult Epithelioid Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)1472005-09-012014-05-23
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
sorafenib tosylate - Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma
Phase 2CompletedNational Cancer Institute (NCI)562005-02-012015-11-20
Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer
imatinib mesylate, laboratory biomarker analysis - Recurrent Uterine Sarcoma, Uterine Carcinosarcoma
Phase 2CompletedNational Cancer Institute (NCI)262004-01-012019-07-24

Narrower conditions

Sarcoma (3)  ·  Carcinoma, Ovarian Epithelial (2)  ·  Fallopian Tube Neoplasms (2)  ·  Histiocytoma, Malignant Fibrous (2)  ·  Leiomyosarcoma (2)  ·  Bone Neoplasms (1)  ·  Chondrosarcoma (1)  ·  Dermatofibrosarcoma (1)  ·  Endometrial Neoplasms (1)  ·  Fibrosarcoma (1)  ·  Hemangiosarcoma (1)  ·  Liposarcoma (1)  ·  Neurofibrosarcoma (1)  ·  Osteosarcoma (1)  ·  Rhabdomyosarcoma (1)

Broader conditions

Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Female Urogenital Diseases (3)  ·  Female Urogenital Diseases and Pregnancy Complications (3)  ·  Genital Diseases (3)  ·  Genital Diseases, Female (3)  ·  Genital Neoplasms, Female (3)  ·  Neoplasms by Site (3)  ·  Neoplasms, Connective Tissue (3)  ·  Neoplasms, Connective and Soft Tissue (3)  ·  Urogenital Diseases (3)  ·  Urogenital Neoplasms (3)  ·  Adnexal Diseases (2)  ·  Carcinoma (2)  ·  Endocrine Gland Neoplasms (2)

Interventions

Sorafenib (2)  ·  Imatinib Mesylate (1)  ·  Radiosurgery (1)  ·  Sirolimus (1)  ·  Sunitinib (1)  ·  aflibercept (1)  ·  angiotensin I (1-7) (1)  ·  saracatinib (1)  ·  temsirolimus (1)

Sponsors

National Cancer Institute (NCI) (7)  ·  Case Comprehensive Cancer Center (1)  ·  Wake Forest University Health Sciences (1)

Countries

United States (9)  ·  Canada (3)

Top investigators

Amit Oza (1)  ·  Gini Fleming (1)  ·  Margaret von Mehren (1)  ·  Mark Einstein (1)  ·  Martee Hensley (1)  ·  Robert DeBernardo, MD (1)  ·  Robert Maki (1)  ·  Warner Huh (1)  ·  William Petty (1)

NIH funding

N01CM62203 (3), N01CM62201 (2), U10CA027469 (2), N01CM00038 (1), N01CM62206 (1), N01CM62209 (1), P30CA008748 (1), P30CA013330 (1)